ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo.
Introducing the STELLUX® Chemi Active GLP-1 (7-36) amide ELISA
Learn more about our STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and how you can now measure active GLP-1 with confidence.
Leveraging Non-Invasive Approaches in NAFLD and NASH Diagnosis and Clinical Research
Dr. Sabina Paglialunga of Celerion addresses the merits and limitations of non-invasive NAFLD/NASH diagnosis and treatment monitoring modalities such as ultrasound, magnetic resonance and elastography. Panels of soluble biomarkers that can distinguish between advanced fibrosis, NASH and fatty liver are also discussed.
ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA 2017
The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader.
ALPCO and InSphero Collaborate to Advance Metabolic Disease Research at ADA 2017
ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays.